利科林通过影响新生的核蛋白Nup93合成来抑制流感病毒的复制
Haiyan Yan1, Huiqiang Wang1, Kun Wang1
1CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
莱科林通过破坏病毒核蛋白出口,有效抑制流感A病毒 (IAV) 和流感B病毒. 这项研究揭示了利科林.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 甲型流感病毒 (IAV) 导致季节性流行病和流行病,需要新的抗病毒治疗.
- 利科林显示广泛的抗病毒特性,但其对IAV的机制尚不清楚.
研究的目的:
- 研究莱科林对流感病毒的抗病毒机制.
- 识别针对宿主的新型抗病毒策略.
主要方法:
- 评估莱科林对IAV和B型流感病毒复制的影响.
- 添加时间和时间过程测试以确定病毒抑制的阶段.
- 研究莱科林对核蛋白Nup93合成和病毒核蛋白 (NP) 核出口的影响.
主要成果:
- 莱科林抑制了病毒mRNA,病毒标位和M2蛋白表达在IAV (H1N1/H3N2) 和B型流感病毒中.
- 利科林干扰了IAV生命周期的晚期阶段.
- 利科林抑制了核蛋白Nup93的新合成,阻断了病毒NP的核出口.
结论:
- 利科林是流感病毒的强有力的抑制剂,包括耐药菌株.
- 利科林通过Nup93抑制来破坏病毒NP核出口.
- 莱科林是广泛的抗流感疗法和宿主向策略的有希望的候选人.
更多相关视频
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
09:35Purification and Visualization of Influenza A Viral Ribonucleoprotein Complexes
Published on: February 9, 2009
相关概念视频
Leaky Scanning
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Types of RNA
RNA Performs Diverse...
